Abstract
The glucocorticoid triamcinolone acetonide is clinically used for the treatment of macular edema. However, the edema-resolving mechanisms of triamcinolone are incompletely understood. Since cell swelling is a central cause of cytotoxic edema in the brain and retina, we determined the effects of triamcinolone acetonide on the swelling of retinal ganglion and Müller glial cells in acutely isolated retinas from rats and guinea pigs in situ. Triamcinolone acetonide (100 μM) had no effect on the swelling of ganglion cells that was evoked in isolated whole mounts of the guinea pig retina by acute application of glutamate (1 mM) or high K+ (50 mM). However, triamcinolone reversed the osmotic swelling of Müller glial cells in retinas of the rat that was observed under various experimental conditions: in retinas isolated at 3 days after transient retinal ischemia, in retinas of eyes with lipopolysaccharide-induced ocular inflammation, and in control retinas in the presence of Ba2+ (1 mM), H2O2 (200 μM), arachidonic acid (10 μM), or prostaglandin E2 (30 nM). The inhibiting effect of triamcinolone on osmotic glial cell swelling was mediated by stimulation of transporter-mediated release of endogenous adenosine and subsequent A1 receptor activation, resulting in an elevation of the intracellular cAMP level and activation of the protein kinase A, and, finally, in an opening of extrusion pathways for K+ and Cl– ions. The inhibitory effect on the cytotoxic swelling of glial cells may contribute to the fast edema-resolving effect of vitreal triamcinolone observed in human patients.
Footnotes
-
This work was supported by Interdisziplinäres Zentrum für Klinische Forschung at the Faculty of Medicine of the University of Leipzig Project C21 and by DFG Grants BR 1249/2-1 and GRK 1097/1.
-
doi:10.1124/jpet.105.092353.
-
ABBREVIATIONS: VEGF, vascular endothelial growth factor; LPS, lipopolysaccharide; PGE2, prostaglandin E2; LY341495, (2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid; DPCPX, 8-cyclopentyl-1,3-dipropylxanthine; CSC, 8-(3-chlorostyryl) caffeine; CPA, N(6)-cyclopentyladenosine; MPEP, 2-methyl-6-(phenylethynyl)-piperidine; BAPTA/AM, bis-(o-aminophenoxy)ethane-N,N,N′,N′-tetra-acetic acid acetoxymethyl ester; pCPT, 8-(4-chlorophenylthio); IBMX, 3-isobutyl-1-methylxanthine; H-89, N-[2-((p-bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide; NPPB, 5-nitro-2-(3-phenylpropylamino)benzoic acid; NBTI, N-nitrobenzylthioinosine; ARL-67156, 6-N,N-diethyl-d-β,γ-dibromomethylene ATP; AOPCP, adenosine-5′-O-(α,β-methylene)-diphosphonate; DMSO, dimethyl sulfoxide.
- Received July 13, 2005.
- Accepted August 31, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|